Not Yet RecruitingPhase 2

LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus

United Kingdom120 participantsStarted 2026-12-01

Plain-language summary

The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are: * To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement. * To identify the optimal length of anticoagulation in the treatment of LV Thrombus After randomisation participants will: * Continue their prescribed oral anticoagulant for the remainder of the trial * Discontinue their prescribed oral anticoagulant for the remainder of the trial

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of LV thrombus less than 12 months ago * On Apixaban at the time of randomisation * Completed at least 3 months of anticoagulation treatment for LV thrombus * Persistent laminar/ mural thrombus or persistent LV dysfunction Exclusion Criteria: * Any clinical condition requiring long term anticoagulation treatment as per investigator's judgement. * SSE since LV thrombus diagnosis * Contraindication to continuing anticoagulation therapy * Non-ischaemic Cardiomyopathy * Age less than 18 years * Unable to consent

What they're measuring

Stroke and Systemic Embolism (SSE)

Timeframe: 6 months

All-Cause Mortality

Timeframe: 6 months

Trial details

NCT IDNCT07246005

SponsorQueen Mary University of London

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-01

Contact for this trial

Dr Dan Jones

02037658707 dan.jones8@nhs.net